Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG - Free Report) in a research report report published on Saturday, May 24th,Weiss Ratings reports.
Other research analysts have also issued reports about the company. The Goldman Sachs Group reduced their target price on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a report on Monday, May 12th. Morgan Stanley reduced their target price on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Stephens reiterated an "overweight" rating and set a $14.00 target price on shares of 10x Genomics in a report on Thursday, May 15th. Barclays reduced their target price on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, Citigroup reduced their target price on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $15.81.
View Our Latest Stock Report on 10x Genomics
10x Genomics Stock Performance
TXG traded up $0.15 during trading on Friday, reaching $9.49. 4,649,181 shares of the company's stock were exchanged, compared to its average volume of 2,426,523. The company's fifty day moving average price is $8.46 and its 200-day moving average price is $11.82. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The firm has a market capitalization of $1.17 billion, a PE ratio of -6.24 and a beta of 1.94.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The firm had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same quarter in the previous year, the business earned ($0.50) EPS. The business's quarterly revenue was down 2.3% compared to the same quarter last year. Research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.
Insider Activity at 10x Genomics
In other 10x Genomics news, CFO Adam Taich sold 4,044 shares of the business's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the sale, the chief financial officer now directly owns 331,588 shares of the company's stock, valued at $2,752,180.40. The trade was a 1.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 9,343 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total transaction of $77,546.90. Following the sale, the chief executive officer now directly owns 1,083,625 shares in the company, valued at $8,994,087.50. This trade represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,872 shares of company stock valued at $173,238. 9.39% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On 10x Genomics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC lifted its position in 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after buying an additional 1,452 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $32,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after purchasing an additional 1,299 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $52,000. Finally, GAMMA Investing LLC raised its holdings in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after purchasing an additional 1,614 shares during the period. 84.68% of the stock is owned by institutional investors.
About 10x Genomics
(
Get Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Articles
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
